HLA-G and neuroblastoma: Furthermore, increased sHLA-G levels have been reported for breast cancer (23–25, 75), hepatocellular carcinoma (31–33), papillary thyroid carcinoma (76), neuroblastoma (37), melanoma (39), colorectal cancer (49, 77), gastric cancer (47, 49), esophageal carcinoma (49–51), lung cancer (49, 54, 55), renal cell carcinoma (62), and acute myeloid leukemia (78).